Regeneron Pharmaceuticals (REGN) Other Non Operating Income (2013 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Other Non Operating Income of $245.3 million for Q2 2026, down 44.6% year-over-year from $442.8 million in Q2 2025, and up 21.92% quarter-over-quarter from $201.2 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Other Non Operating Income (2013 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Other Non Operating Income history runs 14 years deep, the most recent figure standing at $245.3 million for Q2 2026.
- In Q2 2026, Other Non Operating Income fell 44.6% year-over-year to $245.3 million; the TTM figure through Jun 2026 stood at $1.4 billion (up 28.75% YoY), while the FY2025 annual figure was $1.7 billion, up 100.92% from the prior year.
- Other Non Operating Income for Q2 2026 stood at $245.3 million, up from $201.2 million in the prior quarter.
- The five-year high for Other Non Operating Income was $755.8 million in Q3 2025, with the low at -$183.8 million in Q1 2022.
- The 5-year median for Other Non Operating Income is $194.1 million (2022), against an average of $188.4 million.
- Peak annual rise in Other Non Operating Income reached 1937.8% in 2022, while the deepest fall reached 218.66% in 2022.
- Regeneron Pharmaceuticals' Other Non Operating Income stood at $195.3 million in 2022, then fell by 1.18% to $193.0 million in 2023, then slumped by 111.19% to -$21.6 million in 2024, then surged by 914.81% to $176.0 million in 2025, then soared by 39.38% to $245.3 million in 2026.
- Business Quant data shows REGN's Other Non Operating Income at $245.3 million in Q2 2026, $201.2 million in Q1 2026, and $176.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 245.30 Mn |
| Mar 31, 2026 | 201.20 Mn |
| Dec 31, 2025 | 176.00 Mn |
| Sep 30, 2025 | 755.80 Mn |
| Jun 30, 2025 | 442.80 Mn |
| Mar 31, 2025 | 322.00 Mn |
| Dec 31, 2024 | -21.60 Mn |
| Sep 30, 2024 | 327.30 Mn |
| Jun 30, 2024 | 573.30 Mn |
| Mar 31, 2024 | -34.60 Mn |
| Dec 31, 2023 | 193.00 Mn |
| Sep 30, 2023 | 17.60 Mn |
| Jun 30, 2023 | 85.30 Mn |
| Mar 31, 2023 | -70.70 Mn |
| Mar 31, 2022 | -183.80 Mn |
| Dec 31, 2021 | 435.60 Mn |
| Sep 30, 2021 | -16.40 Mn |
| Jun 30, 2021 | 420.00 Mn |
| Mar 31, 2021 | 200,000.00 |
| Dec 31, 2020 | 300,000.00 |